Resilient Becton Dickinson stock trades close to consensus value
Published on 08/22/2026 at 14:14 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS
Becton, Dickinson and Company (ISIN US0718131099) stock is trading just above its latest consensus valuation as of August 21, 2026, with shares highlighted at $187.79 on the NYSE and a market view that centers on a hold recommendation and a consensus price target of $185.67 per share. As recent equity positioning shows, institutional investors have been adding to Becton Dickinson, underlining confidence in the medical technology group despite a premium of $2.12 to the latest target level.
Valuation sits close to consensus target
A recent valuation overview indicates that Becton Dickinson currently trades on a price-to-earnings multiple of 31.7 times, compared with a peer average of 32.6 times and a broader medical equipment industry average of 27.2 times, as of August 21, 2026. This places the shares slightly below the specific peer benchmark but above the wider industry, suggesting that the stock commands a moderate valuation premium that is largely backed by earnings and cash flow generation. In practical terms, the multiple gap of 4.5 points versus the industry average leaves some room for further rerating if margins and growth continue to improve.
According to the latest consensus compiled for Becton Dickinson, the average share price target stands at $185.67, compared with the referenced opening level of $187.79 on August 21, 2026, meaning the stock is trading $2.12 above that level. Expressed as a percentage, this premium comes to 1.1 percent, a small but visible gap that reflects investor willingness to pay slightly more than the collective fair value assessment in order to gain exposure to the company’s portfolio of diagnostic, medical and life science solutions.
Recent earnings and forecasts
From a fundamental perspective, the latest available overview points to annual sales of 20.84 billion for Becton Dickinson and net income of 941 million across its most recently reported full fiscal year, which falls inside the current two-year freshness window relative to August 22, 2026. These totals underscore the group’s scale and its ability to generate profit in a competitive medical technology landscape, with the revenue base supporting continued investment in new products and targeted acquisitions. Against that income level, the reported price-to-earnings ratio in the low-50s range underlines that investors are paying a significant premium for the company’s earnings, consistent with the valuation metrics seen across high-quality healthcare names.
The same data set highlights an earnings-per-share estimate of 4.07 for Becton Dickinson’s next quarter, offering investors a benchmark for near-term performance and a concrete yardstick for assessing upcoming results. If the company meets this estimate, the annualized run rate would align with the current valuation multiples, potentially justifying the modest premium to the consensus target. By contrast, any shortfall versus the 4.07 benchmark could prompt a recalibration of expectations and pressure on the 31.7 times earnings multiple.
In terms of recent momentum, quarterly sales figures show a decline of 9.55 percent compared with the equivalent period of the prior year, reflecting headwinds in specific business lines and tougher comparatives. Even so, the group’s scale and diversified portfolio mean that this single-period contraction does not necessarily define the broader trajectory, and management has signaled a focus on operational efficiency and selective investment to support a return to more sustainable growth over the medium term.
Institutional interest and market positioning
On the ownership side, institutional investors have been active in Becton Dickinson stock, with one featured asset manager disclosing a purchase of 13,396 shares, reinforcing the impression that professional investors view the current valuation as acceptable for adding exposure. While this single transaction is modest relative to the company’s overall float, it illustrates the pattern of incremental accumulation rather than widespread profit-taking, a dynamic that can help support the share price around the mid-$180s.
Market commentary also points to a consensus hold stance on Becton Dickinson, with the average price target of $185.67 functioning as a reference point for both upside and downside analysis. For investors, the fact that the shares trade only a small distance above this level suggests that expectations are neither stretched nor deeply pessimistic, making future earnings surprises and pipeline developments important in determining the next directional move.
Another lens on valuation comes from artificial-intelligence-based forecasting tools, which assign Becton Dickinson a central price target of $189.91, a high scenario of $207.75 and a low scenario of $164.01. At the last indicated price of $187.65, the central AI forecast implies upside of 1.21 percent, while the high scenario would mean a gain of 10.7 percent and the low scenario a decline of 12.6 percent, framing the potential range of outcomes that investors may consider when sizing positions.
Product portfolio and clinical relevance
Becton Dickinson’s core business spans medical devices, diagnostic systems and bioscience tools that are integral to patient care and laboratory work in hospitals and clinics globally. The company is known for its extensive offerings in areas such as syringes, infusion systems, blood collection products and diagnostic platforms that support testing for infectious diseases and chronic conditions. These products generate recurring demand, as healthcare providers must maintain supplies and replace disposable components, contributing to the group’s steady revenue base.
Beyond consumables, Becton Dickinson invests in more sophisticated diagnostic technologies and interventional tools that can improve patient outcomes and workflow efficiency. For example, its solutions in medication management and intravenous therapy aim to reduce dosing errors and streamline nursing tasks, while its diagnostic instruments help laboratories deliver faster and more accurate results. Together, these business segments underpin the earnings profile reflected in the 20.84 billion in sales and 941 million in income referenced in the latest full-year data.
Shares hold around the mid-$180s
As of August 21, 2026, the highlighted level of $187.79 for NYSE:BDX places Becton Dickinson stock just above its consensus target of $185.67, and within a tight trading range centered on the mid-$180s. For investors watching the name, this positioning means that the stock is neither deeply discounted nor aggressively priced, making future movements likely to depend on whether upcoming earnings align with or exceed the 4.07 per-share estimate indicated for the next quarter.
Given this balance, Becton Dickinson’s shares can be seen as occupying a valuation corridor in which even modest changes in guidance, margin trends or product momentum could tip sentiment one way or the other. A solid earnings delivery that confirms the current run rate would tend to support prices around or slightly above the present level, whereas a weaker report could push the shares closer to, or below, the $185.67 consensus anchor.
Fact box
Company: Becton, Dickinson and Company
ISIN: US0718131099
Ticker: BDX
Exchange: NYSE
Price (as of August 21, 2026, 4:00 p.m. ET): $187.79 USD
Sector / Industry: Health care - Medical devices and instruments
